Though imaging techniques are not definitive for PD diagnosis, they still could enhance the diagnostic accuracy by excluding non-degenerative conditions (dopamine transporter or vesicular monoamine transporter 2 and optical coherence tomography of the retina [8,9]), distinguishing PD from secondary parkinsonism or atypical parkinsonism (structural MRI with 50% sensitivity), or contributing in PD differentiation from multiple system atrophy or progressive supranuclear palsy (diffusion-weighted-MRI, fluorodeoxyglucose PET, transcranial ultrasound) [1]. The gene discussed is SLC18A2; the disease is Parkinson disease.